Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Double Blind through Week 24. Partially Blind (to subjects, caregivers, Investigators) through Week 48.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least 18 years of age, (or minimum age as determined by local regulatory or as legal requirements dictate, whichever is higher)
Plasma HIV-1 RNA \> 5000 copies/mL
Antiretroviral treatment-naive; defined as no current or previous exposure to \> 1 week of an antiretroviral drug
CD4+ T-cell count \> 200 cells/mm3
You may not be if
Resistance to any of the study medications \[Tenofovir Disoproxil Fumarate(TDF), Efavirenz (EFV), Lamivudine (3TC)\] or to HIV Protease Inhibitors (PIs)
Contraindications to any of the study drugs
Clareo Health | Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive
